Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide | Zendy

Rayburg Melissa | Zendy; Towbin Alexander | Zendy; Yin Hong | Zendy; Maugans Todd | Zendy; Maurer Barry | Zendy; Nagarajan Rajaram | Zendy; Weiss Brian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide

Author(s) -

Rayburg Melissa,

Towbin Alexander,

Yin Hong,

Maugans Todd,

Maurer Barry,

Nagarajan Rajaram,

Weiss Brian

Publication year - 2009

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.22200

Subject(s) - langerhans cell histiocytosis , medicine , fenretinide , neuroblastoma , blood cancer , histiocytosis , lesion , pathogenesis , pathology , cancer , dermatology , retinoid , disease , retinoic acid , biochemistry , chemistry , genetics , biology , gene , cell culture

Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym‐X‐Sorb (4‐HPR/LXS) powder for neuroblastoma. Pediatr Blood Cancer 2009;53:1111–1113. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research